1
artículo
Publicado 2012
Enlace
Enlace
Toxoplasma gondii and Neospora caninum can cause neuromuscular disorders in dogs. The aim of the Case-Control study was to determine the association between antibodies anti N. caninum and anti-T. gondii in dogs with neuromuscular disorders. Blood samples were collected in 96 and 120 dogs with and without clinical signs of neuromuscular disorders respectively. Serum samples were analyzed by the indirect immunofluorescence test (IFI) for the detection of IgG antibodies, considering positive the sera showing complete fluorescence of the tachyzoite in the dilution 1:50. The frequency for T. gondii was 24.0 ± 8.5% (23/96) and 3.3 ± 3.1 (4/120) for dogs with and without signs of neuromuscular disorders, and for N. caninum was 5.2 ± 4.4 (5/96) and 1.7 ± 2.5 (2/120) for dogs with and without signs of neuromuscular disorders, respectively. There was a significant association between neuromusc...
2
artículo
Publicado 2012
Enlace
Enlace
Toxoplasma gondii y Neospora caninum son causantes de enfermedades neuromusculares en canes. El objetivo de este estudio de Caso-Control fue encontrar la asociación entre la presencia de anticuerpos contra N. caninum y T. gondii en canes con signos clínicos neuromusculares. Se colectó muestras de sangre a 96 y 120 canes con y sin signos clínicos de afección neuromuscular, respectivamente. Los sueros se analizaron con la prueba de Inmunofluorescencia Indirecta (IFI) para la detección de anticuerpos (IgG), donde los sueros con fluorescencia completa del taquizoíto en la dilución 1:50 fueron considerados positivos. La frecuencia para T. gondii fue de 24.0 ± 8.5% (23/96) y de 3.3 ± 3.1 (4/120) para canes con y sin afecciones neuromusculares, respectivamente, y para N. caninum fue de 5.2 ± 4.4 (5/96) y de 1.7 ± 2.5 (2/120) para canes con y sin afecciones neuromusculares, respectiv...
3
artículo
JRBL acknowledges the support from the Peruvian funding agencies OGI-VRI-UNI ( Oficina de Gestión de Investigación-Vicerrectorado de Investigación U.N.I. ) and CONCYTEC-Master scholarship grant N° 167-2015-FONDECYT-UNI.
4
artículo
We present a new process for the extraction of carminic acid (ACAR) from cochineal using mass- separating agent R300 (MSA R300) and an organic solvent with affinity only with the ACAR.
5
artículo
We present a new process for the extraction of carminic acid (ACAR) from cochineal using mass- separating agent R300 (MSA R300) and an organic solvent with affinity only with the ACAR.
6
revisión
Publicado 2023
Enlace
Enlace
The introduction of immunotherapy has brought about a paradigm shift in the management of advanced non-small cell lung cancer (NSCLC). It has not only significantly improved the prognosis of patients but has also become a cornerstone of treatment, particularly in those without oncogenic driver mutations. Immune checkpoint inhibitors (ICIs) play a crucial role in the treatment of lung cancer and can be classified into two main groups: Anti-cytotoxic T lymphocyte antigen-4 (Anti-CTLA-4) and anti-T-cell receptor programmed cell death-1 or its ligand (Anti-PD-1 and Anti-PD-L1). Certainly, the landscape of approved first line immunotherapeutic approaches has expanded to encompass monotherapy, immunotherapy-exclusive protocols, and combinations with chemotherapy. The complexity of decision-making in this realm arises due to the absence of direct prospective comparisons. However, a thorough ana...
7
artículo
Real-world outcomes of anti-EGFR therapy in advanced non–small cell lung cancer EGFR mutated in Peru
Publicado 2023
Enlace
Enlace
Background: Despite the advances in the management of advanced non–small cell lung cancer (NSCLC), the access to genetic profiling and target therapies remains a challenge in Latin America, even in countries with a higher rate of targetable mutations. The aim of this study is to evaluate the clinical outcomes of anti-epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) treatment in a Peruvian real-world setting. Methods: This is a retrospective study of recurrent or advanced NSCLC EGFR mutated patients diagnosed and treated with anti-EGFR TKI at Instituto Nacional de Enfermedades Neoplásicas (INEN) between January 1, 2015 to December 31, 2020. The outcomes were objective response rate (ORR), progression free survival (PFS), and overall survival (OS). Results: We identify 613 stage IV or recurrent NSCLC patients who were tested for EGFR mutations and found a pathoge...
8
artículo
Publicado 2023
Enlace
Enlace
Prostate, breast, colorectal, cervical, and lung cancers are the leading cause of cancer in Latin America and the Caribbean (LAC) accounting for nearly 50% of cancer cases and cancer deaths in the region. Following the IARC Code Against Cancer methodology, a group of Latin American experts evaluated the evidence on several medical interventions to reduce cancer incidence and mortality considering the cancer burden in the region. A recommendation to limit the use of HRT was issued based on the risk associated to develop breast, endometrial, and ovarian cancer and on growing concerns related to the over-the-counter and without prescription sales, which in turn bias estimations on current use in LAC. In alignment with WHO breast and cervical cancer initiatives, biennial screening by clinical breast examination (performed by trained health professionals) from the age of 40 years and biennial...
9
artículo
Publicado 2021
Enlace
Enlace
Background: Thymomas are a group of rare neoplasms of the anterior mediastinum. The objective of this study was to describe the demographics, clinical characteristics and treatment approaches in Latin America.Methods: This was a retrospective multicenter cohort study including patients with histologically proven thymomas diagnosed between 1997 and 2018. Demographics, clinicopathological characteristics and therapeutic outcomes were collected locally and analyzed in a centralized manner. Results: A total of 135 patients were included. Median age at diagnosis was 53 years old (19-84), 53.3% (n = 72) of patients were female and 87.4% had an ECOG performance score ranging from 0-1. A total of 47 patients (34.8%) had metastatic disease at diagnosis. Concurrent myasthenia gravis occurred in 21.5% of patients. Surgery was performed in 74 patients (54.8%), comprising 27 (20%) tumorectomies and 4...
